As of today, RLS has also received its first order from ConvaTec. As of January 1, 2022, ConvaTec will take ownership of the commercial process for ChloraSolv in Europe. The launch of ChloraSolv will take place in various stages with focus during 2022 in the Nordic countries, the Netherlands, the United Kingdom, Germany and France.

"I am pleased that RLS has established a flexibility regarding the financing of our continued growth and that the collaboration with ConvaTec is entering a more active commercialization phase", says Karin Fischer CEO RLS Global.

 RLS' long-term vision is to be a leading research driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as burns and dermatology. To maximize our patient reach, RLS intends to work with partners to commercialize its products globally. RLS is confident in the company's platform technology and its unique features and what this can bring to patients around the world.

Trading place and Certified AdvisEr
RLS Global's shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90,email: certifiedadviser@redeye.se.During the period 2012-2017, the company was listed on Aktietorget.

RLS Global (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation (MAR). The information was submitted for publication through the agency of the above contract person, 19-11-2021 08:30 CET.